For example, Rosiglitazone inhibits CX3CL1 expression and CX3CL1/CX3CR1 signaling by activating peroxisome proliferator-activated receptor γ (PPAR-γ), which can achieve the effect of treating IR and T2DM (151). Here, PPARG is linked to type 2 diabetes mellitus.